MCID: MYL005
MIFTS: 75

Myelofibrosis malady

Bone diseases, Immune diseases categories

Summaries for Myelofibrosis

About this section
Sources:
8Disease Ontology, 42NIH Rare Diseases, 21Genetics Home Reference, 63Wikipedia, 46OMIM, 32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
NIH Rare Diseases:42 Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue. scarring of the bone marrow causes anemia, which can lead to fatigue and weakness, as well as pooling of the blood in abnormal sites like the liver and spleen, causing these organs to swell. although myelofibrosis can occur at any age, it typically develops after the age of 50. in most cases, myelofibrosis gets progressively worse. treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.    last updated: 8/17/2011

MalaCards: Myelofibrosis, also known as primary myelofibrosis, is related to leukemia and polycythemia. An important gene associated with Myelofibrosis is JAK2 (Janus kinase 2), and among its related pathways are Rho Family GTPases and Akt Signaling. The drug busulfan and the compounds tyrosine and vegf have been mentioned in the context of this disorder. Affiliated tissues include the bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue, bone and bone marrow, and related mouse phenotypes are hematopoietic system and cellular.

Disease Ontology:8 A myeloma that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

Genetics Home Reference:21 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.

Wikipedia:63 Myelofibrosis, also known as myeloid metaplasia, chronic idiopathic myelofibrosis, osteomyelofibrosis... more...

Description from OMIM:46 254450

Aliases & Classifications for Myelofibrosis

About this section
Sources:
8Disease Ontology, 42NIH Rare Diseases, 22GTR, 10DISEASES, 44Novoseek, 30LifeMap Discovery™, 60UMLS, 21Genetics Home Reference, 34MeSH, 56SNOMED-CT, 46OMIM, 27ICD9CM, 39NCIt
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Anatomical: Bone diseases, Immune diseases


Aliases & Descriptions:

myelofibrosis 8 42 22 10 44 30 60
primary myelofibrosis 8 42 21 44 60
agnogenic myeloid metaplasia 8 42 21 44
myeloid metaplasia 42 21 44 60
idiopathic myelofibrosis 42 21 44
chronic idiopathic myelofibrosis 8 21
megakaryocytic myelosclerosis 8 60
myelofibrosis with myeloid metaplasia 21
idiopathic bone marrow fibrosis 8
bone marrow fibrosis 8
myelosclerosis, nos 8
aleukemic myelosis 8
myelosclerosis 8


External Ids:

Disease Ontology8 DOID:4971
MeSH34 D055728
OMIM46 254450
ICD9CM27 238.76
NCIt39 C2862

Related Diseases for Myelofibrosis

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Myelofibrosis family:

Familial Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 251)
idRelated DiseaseScoreTop Affiliating Genes
1leukemia31.1IFNA2, BMP6, JAK2, GATA1, STAT5A, THPO
2polycythemia31.1CD177, EPO, IL3, THPO, MPL, STAT5A
3polycythemia vera31.1IFNA2, JAK2, STAT5A, FLT3, MPL, CD177
4acute leukemia30.9THPO, KIT, JAK2, GATA1, STAT5A, FLT3
5primary polycythemia30.8JAK2, STAT5A, EPO
6myeloid leukemia30.6FLT3, MPL, LIF, IL3, IL11, KIT
7osteosclerosis30.6TNFRSF11B, THPO
8thrombocytosis30.4THPO, IL11, IFNA2, JAK2, FLT3, MPL
9vascular disease30.4FGF2, PF4, JAK2
10leukemoid reaction30.4IL3, GATA1
11thrombocytopenia30.3IFNA2, GATA1, MPL, EPO, PF4, IL3
12sarcoma30.3JAK2, KIT, HMGA2, THPO
13megakaryocytic leukemia30.3GATA1, PF4, IL3, IL11, THPO
14pancytopenia30.2THPO, IL3, EPO, MPL
15hepatitis30.2IFNA2, AHSG
16myeloma30.2IFNA2, TNFRSF11B, JAK2, STAT5A, LIF, EPO
17multiple myeloma30.2TNFRSF11B
18obesity30.1JAK2, STAT5A, LIF, AHSG
19uremia30.1TNFRSF11B, EPO, AHSG, PF4
20chronic myeloid leukemia30.1GATA1, STAT5A, FLT3, MPL, CD177, EPO
21chronic myeloproliferative disease30.1JAK2, FLT3, MPL, THPO
22arthritis30.1FGF2, LIF, TNFRSF11B
23peritonitis30.1LIF
24hairy cell leukemia30.1IL3, FLT3, IFNA2
25monocytic leukemia30.1GATA1, LIF
26myeloid sarcoma30.1FLT3, KIT
27hyperparathyroidism30.1TNFRSF11B, EPO
28beta thalassemia30.0EPO, GATA1, TNFRSF11B
29acute lymphocytic leukemia29.9JAK2, GATA1, FLT3, MPL, IL3, KIT
30rheumatoid arthritis29.9TNFRSF11B, BMP6, JAK2, LIF, PF4, IL11
31systemic mastocytosis29.9IFNA2, JAK2, STAT5A, KIT
32hypersplenism29.9THPO
33hepatitis b29.9IFNA2
34hemorrhagic thrombocythemia29.9CD177
35porphyria29.9GATA1
36deficiency anemia29.7THPO, IFNA2, JAK2, GATA1, FLT3, MPL
37breast cancer29.7TNFRSF11B, BMP6, JAK2, STAT5A, FLT3, LIF
38neutropenia29.7IL3, IL11, THPO, EPO, CD177, LIF
39aplastic anemia29.7GATA1, FLT3, MPL, EPO, IL3, IL11
40adenocarcinoma29.7HMGA2, PF4, LIF, STAT5A, JAK2, BMP6
41ovarian cancer29.7IL11, IL3, LIF, JAK2, BMP6
42atherosclerosis29.7TNFRSF11B, BMP6, LIF, AHSG, PF4, FGF2
43glomerulonephritis29.7BMP6
44hypercalcemia29.7LIF, TNFRSF11B
45renal osteodystrophy29.7TNFRSF11B
46adenoma29.7STAT5A, LIF, HMGA2
47down syndrome29.7JAK2, GATA1, FLT3
48tuberculosis29.7IL11, PF4
49acute panmyelosis with myelofibrosis10.4
50acute myeloid leukemia10.4

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to myelofibrosis

Clinical Features for Myelofibrosis

About this section
Sources:
46OMIM
See all sources

Clinical features from OMIM:

254450

Drugs & Therapeutics for Myelofibrosis

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials, 30LifeMap Discovery™, 60UMLS, 40NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Myelofibrosis

Drug clinical trials:

Search ClinicalTrials for Myelofibrosis

Search NIH Clinical Center for Myelofibrosis

Search CenterWatch for Myelofibrosis

Inferred drug relations via UMLS60/NDF-RT40:

Cell-based therapeutics:


LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine
Read about Myelofibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Myelofibrosis

About this section
Sources:
22GTR
See all sources

Genetic tests related to Myelofibrosis:

id Genetic test Affiliating Genes
1 Myelofibrosis22

Anatomical Context for Myelofibrosis

About this section
Sources:
32MalaCards, 14FMA
See all sources

MalaCards organs/tissues related to Myelofibrosis:

32
Bone, Bone marrow, Myeloid, Spleen, Liver, T cells, Endothelial, Monocytes, Nk cells, B cells, Prostate, Lung, Whole blood, Colon, Breast, Lymph node, Brain, Spinal cord, Testes, Kidney, Ovary

FMA organs/tissues related to Myelofibrosis:

14
The bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue

Animal Models for Myelofibrosis or affiliated genes

About this section
Sources:
36MGI
See all sources

MGI Mouse Phenotypes related to Myelofibrosis:

36
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539710.8THPO, TNFRSF11B, JAK2, GATA1, STAT5A, FLT3
2MP:000538410.8STAT5A, GATA1, JAK2, TNFRSF11B, FLT3, MPL
3MP:000537610.8GATA1, STAT5A, FLT3, MPL, LIF, FKBP5
4MP:000537810.7GATA1, JAK2, BMP6, TNFRSF11B, STAT5A, FLT3
5MP:001076810.7FLT3, STAT5A, GATA1, JAK2, TNFRSF11B, MPL
6MP:000538710.7TNFRSF11B, JAK2, GATA1, STAT5A, FLT3, MPL
7MP:001077110.5HMGA2, LIF, GATA1
8MP:000538910.5LIF, BMP6
9MP:000200610.4STAT5A, FLT3, KIT
10MP:000539010.2FGF2, LIF, GATA1, JAK2, TNFRSF11B

Publications for Myelofibrosis

About this section
Sources:
50PubMed
See all sources

Articles related to Myelofibrosis:

(show top 50)    (show all 790)
idTitleAuthorsYear
1
Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. (24359246)
2014
2
Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval. (23647081)
2014
3
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. (23911705)
2013
4
Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis. (23693053)
2013
5
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. (24283870)
2013
6
No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis. (23716550)
2013
7
Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature. (23846384)
2013
8
Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. (24354678)
2013
9
Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. (24066969)
2013
10
Thalidomide-Induced Hemorrhagic Rash in a Patient With Myelofibrosis and Delta-Granule Storage Pool Disease. (24105355)
2013
11
Ruxolitinib: a new treatment for myelofibrosis. (23715708)
2013
12
Hematopoietic stem cell transplantation for myelofibrosis: where are we now? (23314844)
2013
13
Platelet derived growth factor receptor-beta (PDGFRI^) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis. (23748876)
2013
14
Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis) - as one of the reasons of the budd-Chiari syndrome. (22811796)
2012
15
Long-term outcome of pomalidomide therapy in myelofibrosis. (22081489)
2012
16
Primary myelofibrosis and the "bad seeds in bad soil" concept. (23259918)
2012
17
Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature. (22953080)
2012
18
Multiple esophageal variceal ruptures with massive ascites due to myelofibrosis-induced portal hypertension. (22851873)
2012
19
Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab. (22730513)
2012
20
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. (22909192)
2012
21
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (22375970)
2012
22
MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis. (21752469)
2012
23
Clinical and laboratory features of myelofibrosis and limitations of current therapies. (22362131)
2011
24
The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia. (23049351)
2011
25
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. (20029953)
2010
26
Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis! (20859081)
2010
27
Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. (20571018)
2010
28
Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor. (20371117)
2010
29
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. (19549988)
2009
30
Transient myelofibrosis with autoimmune pancytopenia: a case report. (18987883)
2009
31
Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. (19018861)
2009
32
Primary myelofibrosis: update on definition, pathogenesis, and treatment. (18947294)
2009
33
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. (19521323)
2009
34
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. (17350297)
2007
35
Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. (17133423)
2007
36
Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. (17159338)
2007
37
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. (17162218)
2006
38
Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. (16877349)
2006
39
Increased serum thrombopoietin concentration in systemic sclerosis associated with myelofibrosis and thrombocytosis. (16256396)
2006
40
Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. (17064987)
2006
41
Chromosome aberrations including der(6)t(2;6)(p15;p21.3) and der(22)t(3;22)(p21;p11) in the evolution of essential thrombocythemia to myelofibrosis with myeloid metaplasia. (16490605)
2006
42
A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer. (15942101)
2005
43
Acute panmyelosis with myelofibrosis: clinical, immunophenotypic and cytogenetic study of twelve cases. (15223649)
2004
44
Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta. (15060752)
2004
45
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. (14504092)
2004
46
Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. (15036947)
2004
47
Acute panmyelosis with myelofibrosis. (15160939)
2004
48
Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. (10804000)
1999
49
Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. (8435338)
1993
50
Childhood myelofibrosis and osteosclerosis without myeloid metaplasia. (4826622)
1974

Genetic Variations for Myelofibrosis

About this section

Expression for genes affiliated with Myelofibrosis

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Myelofibrosis

Search GEO for disease gene expression data for Myelofibrosis.

Pathways for genes affiliated with Myelofibrosis

About this section
Sources:
51QIAGEN, 29KEGG, 53Reactome, 52R&D Systems, 12EMD Millipore, 37NCBI BioSystems Database, 4Cell Signaling Technology
See all sources

Pathways related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 28)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.6BMP6, JAK2, STAT5A, FLT3, LIF, PF4
2
Hide members
10.6BMP6, JAK2, STAT5A, FLT3, LIF, PF4
3
Hide members
10.6BMP6, JAK2, LIF, PF4, FGF2, IL3
4
Hide members
10.6KIT, TNFRSF11B, JAK2, STAT5A, FLT3, MPL
5
Hide members
10.6BMP6, JAK2, STAT5A, FLT3, FGF2, IL3
610.6IFNA2, JAK2, STAT5A, MPL, LIF, EPO
710.5IFNA2, JAK2, EPO, FGF2, IL3, KIT
8
Hide members
10.5IFNA2, JAK2, GATA1, MPL, CD177, PF4
9
Hide members
10.5BMP6, LIF, FGF2, IL3, KIT, THPO
10
Hide members
10.5BMP6, FLT3, FGF2, IL3, KIT, THPO
11
Hide members
10.5BMP6, FLT3, FGF2, IL3, KIT, THPO
1210.5FLT3, EPO, IL3, IL11, KIT, THPO
13
Hide members
10.5JAK2, STAT5A, MPL, THPO
14
Development Thrombopoetin signaling via JAK-STAT pathway
Hide members
10.5JAK2, STAT5A, MPL, THPO
1510.5KIT, FGF2, FLT3, JAK2
16
Hide members
10.5JAK2, STAT5A, EPO, KIT
17
Hide members
10.5FLT3, FGF2, KIT, THPO
18
Hide members
10.5KIT, FGF2, STAT5A, JAK2
1910.5JAK2, GATA1, STAT5A, IL3
20
Hide members
10.5THPO, IL3, JAK2
21
Hide members
10.5BMP6, FGF2, IL3, THPO
22
Hide members
10.5IL3, FLT3, STAT5A, JAK2
23
Hide members
10.5IL3, STAT5A, JAK2, IFNA2
24
Development EPO-induced Jak-STAT pathway
Hide members
10.5EPO, STAT5A, JAK2
25
Hide members
10.5MPL, THPO
26
Immune response IL-2 activation and signaling pathway
Hide members
10.5IL3, STAT5A, JAK2
2710.5STAT5A, FGF2, IL3, IL11
28
Hide members
10.5BMP6, THPO

Compounds for genes affiliated with Myelofibrosis

About this section
Sources:
44Novoseek, 24HMDB, 49PharmGKB, 11DrugBank, 28IUPHAR, 59Tocris Bioscience, 2BitterDB
See all sources

Compounds related to Myelofibrosis according to GeneCards/GeneDecks:

(show top 50)    (show all 151)
idCompoundScoreTop Affiliating Genes
1tyrosine4411.1MPL, STAT5A, JAK2, BMP6, TNFRSF11B, IFNA2
2vegf4411.0THPO, IL11, FGF2, KIT, PF4, EPO
3gp 1304411.0TNFRSF11B, BMP6, JAK2, STAT5A, FLT3, MPL
4thymidine44 2412.0JAK2, BMP6, IFNA2, STAT5A, PF4, THPO
5retinoic acid44 2412.0JAK2, THPO, HMGA2, IL11, IL3, BMP6
6phosphatidylinositol4411.0FLT3, THPO, KIT, IL11, IL3, FGF2
7cytarabine44 49 1113.0EPO, IL3, IL11, KIT, THPO, LIF
8agar4411.0LIF, MPL, IFNA2, THPO, FGF2, PF4
9methylcellulose4411.0IL11, THPO, FLT3, LIF, EPO, FGF2
10anagrelide44 1112.0IFNA2, JAK2, MPL, EPO, PF4, THPO
11hydroxyurea44 49 1113.0PF4, THPO, GATA1, EPO, IL3, IFNA2
12cyclosporin a44 28 5913.0JAK2, IL3, FGF2, IL11, FKBP5, LIF
13cysteine4411.0IL3, STAT5A, JAK2, MPL, AHSG, PF4
14imatinib44 49 1113.0FLT3, THPO, STAT5A, IL3, JAK2, KIT
15steroid4411.0FKBP5, GATA1, IFNA2, THPO, LIF, STAT5A
16rapamycin4411.0STAT5A, FLT3, JAK2, BMP6, EPO, THPO
17filgrastim44 1111.9THPO, IL11, IL3, EPO, IFNA2, LIF
18tgf beta14410.9IL11, THPO, PF4, TNFRSF11B, FLT3, BMP6
19estrogen4410.9AHSG, THPO, GATA1
20gm-csf44 2811.9THPO, STAT5A, IL11, LIF
21doxorubicin44 49 1112.9HMGA2, KIT, IL11, IL3, GATA1, FLT3
22pixy3214410.9THPO, EPO, IL3, IL11, FLT3
235fluorouracil4410.9THPO, MPL, KIT, IL11, IL3, PF4
24cycloheximide4410.9GATA1, FKBP5
25aspartate4410.9IL11, FLT3, GATA1, STAT5A, BMP6, JAK2
2612-o-tetradecanoylphorbol 13-acetate4410.9GATA1, IFNA2, IL11, IL3, PF4, LIF
27hydrocortisone44 2 59 1113.9FGF2, TNFRSF11B, LIF, STAT5A, EPO
28pd 98,0594410.9STAT5A, JAK2, FGF2, IL3, KIT, BMP6
29ly2940024410.9STAT5A, FGF2, BMP6, IL3, THPO, TNFRSF11B
30herbimycin a44 5911.9IL3, FGF2, BMP6, JAK2, STAT5A, IL11
31alanine4410.9STAT5A, MPL, PF4, JAK2, FGF2, IL3
32dexamethasone44 49 28 1113.9IL3, TNFRSF11B, FKBP5, FGF2, BMP6, LIF
33carboplatin44 49 1112.9THPO, EPO, IL11, IFNA2, LIF, IL3
34actinomycin d4410.9KIT, GATA1, JAK2, LIF, FGF2, IL3
35indomethacin44 59 28 1113.8PF4
36calcitriol44 59 11 2413.8IL11, BMP6, LIF, EPO, TNFRSF11B, IL3
37polyethylene glycol4410.8IFNA2, BMP6, PF4, IL11, THPO, MPL
38progesterone44 59 28 11 2414.8KIT, IL11, FKBP5, LIF, STAT5A, GATA1
39il 114410.8LIF, IL11, EPO, IL3
40azathioprine44 49 2 1113.8TNFRSF11B, IL11, EPO, GATA1, IFNA2, LIF
41rantes4410.7THPO, IL3, PF4, LIF, BMP6, IL11
42lactate4410.7BMP6, FLT3, PF4, LIF, EPO, IL3
43etoposide44 49 59 1113.7IL3, THPO, IFNA2, STAT5A, FLT3, PF4
44oligonucleotide4410.7GATA1, THPO, IL11, KIT, LIF, FLT3
45ascorbic acid44 2411.6LIF, EPO, FGF2, IL3, JAK2, TNFRSF11B
46glucose4410.6AHSG, IFNA2, PF4, IL11, LIF
47sb 20358044 5911.5TNFRSF11B, BMP6, THPO, LIF, STAT5A, JAK2
48butyrate4410.5JAK2, THPO, IL11, GATA1
49ag-12964410.4FLT3, KIT, IL3, STAT5A
50amifostine44 1111.2THPO, IL11, IL3, EPO

GO Terms for genes affiliated with Myelofibrosis

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00557610.5TNFRSF11B, EPO, AHSG, PF4, FGF2, IL3
2extracellular spaceGO:00561510.3THPO, IFNA2, TNFRSF11B, BMP6, LIF, EPO

Biological processes related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cell proliferationGO:00828410.9KIT, JAK2, FLT3, LIF, EPO, FGF2
2blood coagulationGO:00759610.9IFNA2, JAK2, GATA1, MPL, CD177, PF4
3positive regulation of tyrosine phosphorylation of Stat5 proteinGO:04252310.9KIT, IL3, EPO, JAK2
4positive regulation of peptidyl-tyrosine phosphorylationGO:05073110.9JAK2, GATA1, LIF, IL3, IL11
5positive regulation of tyrosine phosphorylation of Stat3 proteinGO:04251710.9KIT, LIF, JAK2, IFNA2
6peptidyl-tyrosine phosphorylationGO:01810810.9KIT, FLT3, STAT5A, JAK2
7positive regulation of transcription from RNA polymerase II promoterGO:04594410.9BMP6, GATA1, STAT5A, LIF, FGF2, IL11
8cytokine-mediated signaling pathwayGO:01922110.8KIT, PF4, FLT3, JAK2, IFNA2
9positive regulation of MAPK cascadeGO:04341010.8FLT3, LIF, IL11, KIT
10embryonic hemopoiesisGO:03516210.8GATA1, IL3, KIT
11negative regulation of cell proliferationGO:00828510.8JAK2, GATA1, FLT3, LIF, FGF2
12erythrocyte differentiationGO:03021810.8KIT, GATA1, JAK2
13positive regulation of phosphatidylinositol 3-kinase activityGO:04355210.8KIT, FGF2, FLT3
14positive regulation of phosphatidylinositol 3-kinase cascadeGO:01406810.8KIT, FLT3, JAK2
15tyrosine phosphorylation of Stat3 proteinGO:04250310.8JAK2, LIF
16myeloid progenitor cell differentiationGO:00231810.7FLT3, KIT
17mammary gland epithelium developmentGO:06118010.7STAT5A, JAK2
18platelet activationGO:03016810.7MPL, PF4, IL11, THPO
19positive regulation of phospholipase C activityGO:01086310.7KIT, FGF2
20megakaryocyte differentiationGO:03021910.7IL11, GATA1
21dendritic cell differentiationGO:09702810.6GATA1, FLT3
22positive regulation of tyrosine phosphorylation of Stat1 proteinGO:04251110.6LIF, KIT
23cell-cell signalingGO:00726710.6IFNA2, GATA1, IL3, IL11
24male gonad developmentGO:00858410.5HMGA2, KIT, GATA1
25positive regulation of macrophage differentiationGO:04565110.5LIF, PF4
26cellular response to thyroid hormone stimulusGO:09706710.4KIT, GATA1
27negative regulation of hormone secretionGO:04688810.2LIF, IL11

Molecular functions related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1C2H2 zinc finger domain bindingGO:07074210.5HMGA2, GATA1
2cytokine activityGO:00512510.4THPO, IFNA2, TNFRSF11B, BMP6, LIF, FGF2
3growth factor activityGO:00808310.2BMP6, LIF, FGF2, IL3, IL11, THPO

Products for genes affiliated with Myelofibrosis

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Myelofibrosis

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet